Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
A Systematic Review and Meta-Analysis: Memantine Augmentation in Moderate to Severe Obsessive-Compulsive Disorder Publisher Pubmed



Modarresi A1 ; Chaibakhsh S1, 2 ; Koulaeinejad N3 ; Koupaei SR4
Authors
Show Affiliations
Authors Affiliations
  1. 1. Research Center for Rational Use of Drugs, Tehran University of Medical Sciences, Tehran, Iran
  2. 2. Neuromusculoskeletal Research Center, Iran University of Medical Sciences, Tehran, Iran
  3. 3. Department of Clinicl Pharmacy, Faculty of Pharmacy, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran
  4. 4. Core trainee in psychiatry, Cambridge and Peterborough Foundation Trust, Cambridge, United Kingdom

Source: Psychiatry Research Published:2019


Abstract

A considerable proportion of obsessive-compulsive disorder (OCD) patients receiving first-line pharmacological therapy, fail to fully respond to treatment and continue to exhibit significant symptoms. In this systematic review, we evaluate the efficacy of memantine, as a glutamate-modulating agent, in moderate to severe OCD. Single and double blinded as well as open-label trials of memantine augmentation in adults with OCD were considered. Yale-Brown Obsessive Compulsive Scale (Y-BOCS) scores were the primary outcome measure. The electronic databases of PubMed, Scopus, Embase and Google Scholar were searched for relevant trials using keywords ‘obsessive-compulsive disorder OR OCD’ AND ‘memantine’. The meta-analysis of eight studies involving 125 OCD subjects receiving memantine augmentation exhibited a significant overall mean reduction of 11.73 points in Y-BOCS scores. The categorical analysis of treatment response (a minimum of 35% reduction in Y-BOCS) in four double-blind placebo-controlled studies indicated that OCD patients receiving memantine augmentation were 3.61 times more likely to respond to treatment than those receiving placebo. We found that 20 mg/day memantine augmentation to first-line pharmacological treatment for a period of at least 8 weeks is a safe and effective intervention for moderate to severe OCD. © 2019
Related Docs
View other Related Docs
1. Memantine Augmentation Improves Symptoms in Serotonin Reuptake Inhibitor-Refractory Obsessive-Compulsive Disorder: A Randomized Controlled Trial, Pharmacopsychiatry (2018)
2. L-Carnosine As an Adjuvant to Fluvoxamine in Treatment of Obsessive Compulsive Disorder: A Randomized Double-Blind Study, Human Psychopharmacology (2017)
3. Minocycline Combination Therapy With Fluvoxamine in Moderate-To-Severe Obsessive–Compulsive Disorder: A Placebo-Controlled, Double-Blind, Randomized Trial, Psychiatry and Clinical Neurosciences (2016)
4. Riluzole in Augmentation of Fluvoxamine for Moderate to Severe Obsessive–Compulsive Disorder: Randomized, Double-Blind, Placebo-Controlled Study, Psychiatry and Clinical Neurosciences (2016)
5. N-Acetylcysteine Augmentation Therapy for Moderate-To-Severe Obsessive-Compulsive Disorder: Randomized, Double-Blind, Placebo-Controlled Trial, Journal of Clinical Pharmacy and Therapeutics (2016)
6. L-Theanine Combination Therapy With Fluvoxamine in Moderate-To-Severe Obsessive–Compulsive Disorder: A Placebo-Controlled, Double-Blind, Randomized Trial, Psychiatry and Clinical Neurosciences (2023)
7. Amantadine As Adjuvant Therapy in the Treatment of Moderate to Severe Obsessive–Compulsive Disorder: A Double-Blind Randomized Trial With Placebo Control, Psychiatry and Clinical Neurosciences (2019)
8. Repetitive Transcranial Magnetic Stimulation (Rtms) Improves Symptoms and Reduces Clinical Illness in Patients Suffering From Ocd - Results From a Single-Blind, Randomized Clinical Trial With Sham Cross-Over Condition, Journal of Psychiatric Research (2015)
Experts (# of related papers)
View all Related Experts
Shahin Akhondzadeh Basti (11)
Farzin Rezaei (3)
Other Related Docs
9. Glutamatergic Medications As Adjunctive Therapy for Moderate to Severe Obsessive-Compulsive Disorder in Adults: A Systematic Review and Meta-Analysis, BMC Pharmacology and Toxicology (2021)
10. Correlations Between Single Nucleotide Polymorphisms in Obsessive-Compulsive Disorder With the Clinical Features or Response to Therapy, Journal of Psychiatric Research (2023)
11. Comparison of Saffron and Fluvoxamine in the Treatment of Mild to Moderate Obsessive-Compulsive Disorder: A Double Blind, Randomized Clinical Trial, Iranian Journal of Psychiatry (2017)
12. Effectiveness of Memantine on Depression-Like Behavior, Memory Deficits and Brain Mrna Levels of Bdnf and Trkb in Rats Subjected to Repeated Unpredictable Stress, Pharmacological Reports (2018)
13. Fluvoxamine Combination Therapy With Tropisetron for Obsessive-Compulsive Disorder Patients: A Placebo-Controlled, Randomized Clinical Trial, Journal of Psychopharmacology (2019)
14. A Comparative, Single-Blind, Randomized Study on Quetiapine and Aripiperazole Augmentation in Treatment of Selective Serotonin Reuptake Inhibitor Refractory Obsessive-Compulsive Disorder, Canadian Journal of Physiology and Pharmacology (2020)
15. The Safety and Efficacy of Transcranial Direct Current Stimulation As Add-On Therapy to Fluoxetine in Obsessive-Compulsive Disorder: A Randomized, Double-Blind, Sham-Controlled, Clinical Trial, BMC Psychiatry (2020)
16. The Efficacy of Aripiprazole Versus Risperidone As Augmentation Therapy in Treatment-Resistant Obsessive-Compulsive Disorder: A Double Blind Clinical Trial, Iranian Red Crescent Medical Journal (2018)
17. Food Insecurity Is Associated With the Sleep Quality and Quantity in Adults: A Systematic Review and Meta-Analysis, Public Health Nutrition (2023)
18. Prevalence Rate of Hepatitis B Virus in Pregnancy: Implications From a Systematic Review and Meta-Analysis of Studies Published From 2000 to 2016, Hepatitis Monthly (2018)
19. Repetitive Transcranial Magnetic Stimulation Improved Symptoms of Obsessive-Compulsive Disorder, But Also Cognitive Performance: Results From a Randomized Clinical Trial With a Cross-Over Design and Sham Condition, Neuropsychobiology (2016)
20. Effect of Memantine Combination Therapy on Symptoms in Patients With Moderate-To-Severe Depressive Disorder: Randomized, Double-Blind, Placebo-Controlled Study, Journal of Clinical Pharmacy and Therapeutics (2017)
21. Cerebellar Microstructural Abnormalities in Obsessive–Compulsive Disorder (Ocd): A Systematic Review of Diffusion Tensor Imaging Studies, Cerebellum (2024)
22. The Prevalence and Clinical Features of Amphetamine-Induced Obsessive Compulsive Disorder, Drug and Alcohol Dependence (2016)
23. 5-Hydroxytryptophan As Adjuvant Therapy in Treatment of Moderate to Severe Obsessive-Compulsive Disorder: A Double-Blind Randomized Trial With Placebo Control, International Clinical Psychopharmacology (2020)
24. Efficacy of N-Acetylcysteine Augmentation on Obsessive Compulsive Disorder: A Multicenter Randomized Double Blind Placebo Controlled Clinical Trial, Iranian Journal of Psychiatry (2017)